Terumo Corporation
IFRS Financial Results for the Second Quarter of
the Fiscal Year Ending March 31, 2021

－1－

－ 2－

4. Consolidated Financial Statements① Consolidated Statement of Financial Position（Unit: Millions of yen）
As of
September 30, 2020

As ofMarch 31, 2020
AssetsCurrent assets
Cash and cash equivalents

166,898

209,577

Trade and other receivables

131,728

119,334

Other current financial assets

397

177

147,147

167,011

Current tax assets

1,745

1,712

Other current assets

12,68914,949Total current assets

460,607

512,762

Property, plant and equipment

264,407274,382

Goodwill and intangible assets

461,506

452,192

Inventories

Non-current assets

Investments accounted for using
the equity method
Other non-current financial assets

5,275

3,499

17,733

16,651

Deferred tax assets

27,30728,658Other non-current assets

4,517

4,286

Total non-current assets

780,748779,669

1,241,355

1,292,432

Total assets－ 3－

（Unit: Millions of yen）
As of
September 30, 2020

As ofMarch 31, 2020
Liabilities and Equity
Liabilities
Current liabilities
Trade and other payables

88,04473,894

Bonds and borrowings

50,32450,484

Other current financial liabilities

6,144

7,154

Current tax liabilities

11,681

12,659395

330

Other current liabilities

55,256

52,691

Total current liabilities

211,845

197,215

Bonds and borrowings

195,870

246,898

Other non-current financial liabilities

31,80235,335

Deferred tax liabilities

20,36018,117

Defined benefit liabilities

18,456

16,601

92

91

Other non-current liabilities

8,043

8,819

Total non-current liabilities

274,626

325,862

486,472

523,078

Share capital

38,716

38,716

Capital surplus

51,85851,730Treasury shares(14,103)(7,755)Retained earnings

705,765

728,593

Other components of equity(27,423)(41,916)

Total equity attributable to ownersof the parent
Non-controlling interests

754,813769,367

69(14)

Total equity

754,883

769,353

1,241,355

1,292,432

Provisions

Non-current liabilities

Provisions

Total liabilities
EquityTotal liabilities and equity－ 4－

② Consolidated Statement of Profit or Loss
For the six months ended
September 30, 2019
307,278
135,815
171,463
113,9443,0941,462
59,150915
1,909（Unit: Millions of yen）
For the six months ended
September 30, 2020
283,296
132,832
150,463
109,026
1,757
1,369
41,824581
1,027(92)(719)

58,065
12,44345,62140,6598,900
31,759Attributable to:
Owners of the parent
Non-controlling interests
Total profit for the period

45,711(89)
45,621

31,842(83)
31,759Earnings per share
Basic earnings per share (yen)Diluted earnings per share (yen)

61.44
60.42

42.21
42.08

Revenue
Cost of sales
Gross profit
Selling, general and administrative expensesOther income
Other expenses
Operating profit
Finance income
Finance costs
Share of profit (loss) of investments accounted
for using the equity method
Profit before tax
Income tax expenses
Profit for the period－ 5－

③ Consolidated Statement of Comprehensive Income

Profit for the period

For the six months ended
September 30, 201945,621（Unit: Millions of yen）
For the six months ended
September 30, 2020
31,759

(292)

663

(450)

136

(742)

799

(24,509)(14,299)

(80)

141

(65)

414

(24,655)(13,743)(25,397)(12,943)

20,224

18,8152,031018,898(85)(83)

20,224

18,815

Other comprehensive income
Items that will not be reclassified to profit or loss
Changes in financial assets measured at fair value
through other comprehensive income
Remeasurement of defined benefit plan
Total items that will not be reclassified toprofit or loss
Items that are or may be reclassified
subsequently to profit or loss
Exchange differences on translation offoreign operations
Cash flow hedges
Cost of hedging
Total items that are or may be reclassified
subsequently to profit or loss
Total other comprehensive income (loss)
for the period
Total comprehensive income for the period
Attributable toOwners of the parent
Non-controlling interests
Total comprehensive income for the period(Note)

Items in the above statement are net of tax.

－ 6－④ Consolidated Statements of Changes in Equity（Unit: Millions of yen）
Share
capitalBalance as of April 1, 2019

38,716Equity attributable to the owners of the parent
Other
CapitalTreasury
Retainedcomponents
surplussharesearningsof equity

52,029(32,381)646,223

Profit for the period(6,553)45,711

Total comprehensive income
Acquisition of treasury shares(1)

Disposal of treasury shares

65

(20)

Dividends

Total

698,034

78

698,11345,711(89)

45,621(25,401)(25,401)3(25,397)(25,401)

20,310(85)

20,22445,711Other comprehensive income

Noncontrollinginterests

Total

(1)

(1)

00(10,029)(10,029)(44)(10,029)

Transfer from other components ofequity to retained earnings
Change in shares of subsidiaries due
to capital increase
Share-based payments

(152)

120

82

Conversion of convertible bonds(73)

10,589

(159)

(226)

10,774(10,577)

426

397

53

450

51,803(21,607)

681,358(31,527)

718,74146

718,788

Total transactions with the owners ofthe parent
Balance as of September 30, 2019

(450)

450
53

38,716

2053

71

71

10,356

10,356（Unit: Millions of yen）
Share
capitalBalance as of April 1, 2020

38,716Equity attributable to the owners of the parent
Other
CapitalTreasury
Retainedcomponents
surplussharesearnings
of equity

51,858(14,103)705,765

Profit for the period

31,842

Total comprehensive income
Acquisition of treasury shares(0)

Disposal of treasury shares

430

Dividends

69754,883

31,842(83)31,759(12,943)(12,943)(0)(12,943)(12,943)

18,898(83)

18,815(43)(10,531)Transfer from other components ofequity to retained earnings
Share-based payments(100)

Conversion of convertible bonds

38,716

(0)

(0)

00

(10,531)(10,531)

125

125

6,062

6,062
(4,344)

1,529(1,529)99

102

24(27)

6,206

(116)

(128)

6,347

(9,015)(1,548)(4,344)51,730(7,755)728,593(41,916)

769,367

－ 7－

Total

754,81331,842Other comprehensive income

Total transactions with the owners ofthe parent
Balance as of September 30, 2020

(27,423)

Noncontrollinginterests

Total(14)769,353

⑤ Segment informatition▪ Reportable segment information

Revenue and operating results of the reportable segments of the Group are described below.
▪ Changes in name of reportable segment

The segment previously named “Blood Management Company” was changed to “Blood and Cell Technologies
Company” from the fiscal year ended March 31, 2020. This change in name does not affect the segment information.
The name of reportable segment for the fiscal year ended September 30, 2019 was also revised to “Blood and CellTechnologies Company”.
For the six months ended September 30, 2019
（Unit: Millions of yen）
Reportable Segments

Revenue
Revenue from sales toexternal customers
Segment Profit(Adjusted operatingprofit)(Adjustment item）
Amortization of intangible
assets acquired throughbusiness combinations
Non-recurring profit orloss (Note 2)

Adjustments(Note 1)

Amountrecorded on
consolidated
financialstatements

307,168110

307,278

6,686

66,457587

67,044(4,100)(7,618)(228)(7,847)

Cardiacand
VascularCompanyGeneral
HospitalCompany

Blood andCell
Technologies
Company

172,597

82,81551,75647,177

12,592(3,518)

Total(47)

Operating profit

59,150Finance income

915

Finance costs
Share of profit/(loss) ofinvestment accounted forusing the equity method(1,909)Profit before tax

58,065(92)(Note 1) Amounts in ‘Adjustments’ are as follows:(1) ¥110 million adjustment to revenue from sales to external customers is mainly proceeds from temporary
staffing that is not attributable to reportable segments.
(2) ¥587 million adjustment to segment profit consists of ¥202 million for “inventories”.
(Note 2) ¥(47) million Non-recurring profit or loss mainly includes ¥1,167 million insurance revenue about hurricane in
Puerto Rico in 2017 and ¥(894) million for business reorganization expenses.

－ 8－For the six months ended September 30, 2020
Reportable Segments

Revenue
Revenue from sales toexternal customers
Segment Profit(Adjusted operatingprofit)(Adjustment item）
Amortization of intangible
assets acquired throughbusiness combinations
Non-recurring profit orloss (Note 2)

Adjustments(Note 1)

Amountrecorded on
consolidated
financialstatements

283,169127

283,296

8,880

52,616(1,355)51,261(4,037)(7,516)340(7,176)

CardiacandVascularCompanyGeneral
HospitalCompany

Blood andCell
Technologies
Company

149,424

81,791

51,95232,017

11,718(3,479)Total(2,259)

Operating profit

41,824

Finance income

581

Finance costs
Share of profit/(loss) ofinvestment accounted forusing the equity method(1,027)

Profit before tax

40,659(719)(Note 1) Amounts in ‘Adjustments’ are as follows:(1) ¥127 million adjustment to revenue from sales to external customers is mainly proceeds from temporary
staffing that is not attributable to reportable segments.
(2) ¥(1,355) million adjustment to segment profit consists of ¥385 million for “inventories” ,¥(1,189) million for
preparation expenses to comply with Medical Device Regulation in EU.
(Note 2) ¥(2,259) million Non-recurring profit or loss mainly includes ¥(1,852) million for the change in fair value ofcontingent consideration and ¥(321) million for business reorganization expenses.

－ 9－